Rabbit Recombinant Monoclonal PKC delta phospho S645 antibody. Suitable for IHC-P, ELISA, Dot, WB and reacts with Human, Synthetic peptide, Synthetic peptide - Human samples. Cited in 5 publications.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
IHC-P | ELISA | Dot | WB | ICC/IF | IP | Flow Cyt | |
---|---|---|---|---|---|---|---|
Human | Tested | Expected | Expected | Tested | Not recommended | Not recommended | Not recommended |
Synthetic peptide | Not recommended | Tested | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Synthetic peptide - Human | Not recommended | Not recommended | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 | Notes Antigen retrieval is recommended. Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide, Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10000 - 1/50000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide, Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Synthetic peptide, Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Synthetic peptide, Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Synthetic peptide, Synthetic peptide - Human | Dilution info - | Notes - |
Select an associated product type
Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays contrasting roles in cell death and cell survival by functioning as a pro-apoptotic protein during DNA damage-induced apoptosis, but acting as an anti-apoptotic protein during cytokine receptor-initiated cell death, is involved in tumor suppression as well as survival of several cancers, is required for oxygen radical production by NADPH oxidase and acts as positive or negative regulator in platelet functional responses (PubMed:21406692, PubMed:21810427). Negatively regulates B cell proliferation and also has an important function in self-antigen induced B cell tolerance induction (By similarity). Upon DNA damage, activates the promoter of the death-promoting transcription factor BCLAF1/Btf to trigger BCLAF1-mediated p53/TP53 gene transcription and apoptosis (PubMed:21406692, PubMed:21810427). In response to oxidative stress, interact with and activate CHUK/IKKA in the nucleus, causing the phosphorylation of p53/TP53 (PubMed:21406692, PubMed:21810427). In the case of ER stress or DNA damage-induced apoptosis, can form a complex with the tyrosine-protein kinase ABL1 which trigger apoptosis independently of p53/TP53 (PubMed:21406692, PubMed:21810427). In cytosol can trigger apoptosis by activating MAPK11 or MAPK14, inhibiting AKT1 and decreasing the level of X-linked inhibitor of apoptosis protein (XIAP), whereas in nucleus induces apoptosis via the activation of MAPK8 or MAPK9. Upon ionizing radiation treatment, is required for the activation of the apoptosis regulators BAX and BAK, which trigger the mitochondrial cell death pathway. Can phosphorylate MCL1 and target it for degradation which is sufficient to trigger for BAX activation and apoptosis. Is required for the control of cell cycle progression both at G1/S and G2/M phases. Mediates phorbol 12-myristate 13-acetate (PMA)-induced inhibition of cell cycle progression at G1/S phase by up-regulating the CDK inhibitor CDKN1A/p21 and inhibiting the cyclin CCNA2 promoter activity. In response to UV irradiation can phosphorylate CDK1, which is important for the G2/M DNA damage checkpoint activation (By similarity). Can protect glioma cells from the apoptosis induced by TNFSF10/TRAIL, probably by inducing increased phosphorylation and subsequent activation of AKT1 (PubMed:15774464). Is highly expressed in a number of cancer cells and promotes cell survival and resistance against chemotherapeutic drugs by inducing cyclin D1 (CCND1) and hyperphosphorylation of RB1, and via several pro-survival pathways, including NF-kappa-B, AKT1 and MAPK1/3 (ERK1/2). Involved in antifungal immunity by mediating phosphorylation and activation of CARD9 downstream of C-type lectin receptors activation, promoting interaction between CARD9 and BCL10, followed by activation of NF-kappa-B and MAP kinase p38 pathways (By similarity). Can also act as tumor suppressor upon mitogenic stimulation with PMA or TPA. In N-formyl-methionyl-leucyl-phenylalanine (fMLP)-treated cells, is required for NCF1 (p47-phox) phosphorylation and activation of NADPH oxidase activity, and regulates TNF-elicited superoxide anion production in neutrophils, by direct phosphorylation and activation of NCF1 or indirectly through MAPK1/3 (ERK1/2) signaling pathways (PubMed:19801500). May also play a role in the regulation of NADPH oxidase activity in eosinophil after stimulation with IL5, leukotriene B4 or PMA (PubMed:11748588). In collagen-induced platelet aggregation, acts a negative regulator of filopodia formation and actin polymerization by interacting with and negatively regulating VASP phosphorylation (PubMed:16940418). Downstream of PAR1, PAR4 and CD36/GP4 receptors, regulates differentially platelet dense granule secretion; acts as a positive regulator in PAR-mediated granule secretion, whereas it negatively regulates CD36/GP4-mediated granule release (PubMed:19587372). Phosphorylates MUC1 in the C-terminal and regulates the interaction between MUC1 and beta-catenin (PubMed:11877440). The catalytic subunit phosphorylates 14-3-3 proteins (YWHAB, YWHAZ and YWHAH) in a sphingosine-dependent fashion (By similarity). Phosphorylates ELAVL1 in response to angiotensin-2 treatment (PubMed:18285462). Phosphorylates mitochondrial phospholipid scramblase 3 (PLSCR3), resulting in increased cardiolipin expression on the mitochondrial outer membrane which facilitates apoptosis (PubMed:12649167). Phosphorylates SMPD1 which induces SMPD1 secretion (PubMed:17303575).
PKCD, PKCD, PRKCD, Protein kinase C delta type, Tyrosine-protein kinase PRKCD, nPKC-delta
Rabbit Recombinant Monoclonal PKC delta phospho S645 antibody. Suitable for IHC-P, ELISA, Dot, WB and reacts with Human, Synthetic peptide, Synthetic peptide - Human samples. Cited in 5 publications.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EP1486Y
Affinity purification Protein A
Blue Ice
+4°C
-20°C
Stable for 12 months at -20°C
This product has switched from a hybridoma to recombinant production method on 20th November 2023.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
Protein kinase C delta (PKC delta) often called PKCδ belongs to the novel PKC subfamily. It weighs approximately 78 kDa and functions in various cellular processes. This enzyme exhibits serine/threonine kinase activity and is expressed across numerous tissues including the brain heart and lymphoid organs. PKC delta activation mainly relies on diacylglycerol and phospholipids though it does not require calcium for activation. This target has multiple known phosphorylation sites such as delta 1485 and delta 647 that modulate its enzymatic activity and localization.
PKC delta influences cell growth apoptosis and differentiation through its kinase activity. It acts as an important regulator in the signaling pathways that control these processes. PKC delta is not a part of a traditional complex but interacts with several proteins influencing signaling cascades. In cellular contexts PKC delta positively influences tumor necrosis factor-related pathways and also initiates apoptosis in response to DNA damage.
PKC delta plays an essential role in the regulation of mitogen-activated protein kinase (MAPK) and Janus kinase (JAK) pathways. Within the MAPK pathway PKC delta interacts with proteins like c-Jun N-terminal kinase (JNK) facilitating stress-responsive pathways related to cell death and survival. In the JAK pathway its regulation can impact cytokine signaling and immune responses. PKC delta's function within these pathways positions it as an important mediator and influencer of diverse cellular responses.
PKC delta has significant implications for cancer and cardiovascular diseases. PKC delta promotes tumor cell proliferation in some cancers by altering cell cycle regulation and resist apoptosis. In cardiovascular disorders this protein mediates cardiac hypertrophy and heart failure through its influence on myocyte apoptosis and fibrosis. PKC delta’s interaction with specific proteins like Bcl-2 in cancer and troponin in cardiac conditions highlights its role in pathophysiological processes making it a significant target for therapeutic intervention.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lanes 1, 5 and 9: Wild-type HAP1 cell lysate (20 μg)
Lanes 2, 6 and 10: PKC delta knockout HAP1 cell lysate (20 μg)
Lanes 3, 7 and 11: A431 cell lysate (20 μg)
Lanes 4, 8 and 12: HeLa cell lysate (20 μg)
Lanes 1, 2, 3 and 4: Green signal from target – ab108972 observed at 78 kDa
Lanes 5, 6, 7 and 8: Red signal from loading control – Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa
Lanes 9, 10, 11 and 12: Merged (red and green) signal
ab108972 was shown to specifically react with PKC delta when PKC delta knockout samples were used. Wild-type and PKC delta knockout samples were subjected to SDS-PAGE. ab108972 and Anti-GAPDH antibody [6C5] - Loading Control ab8245 (loading control to GAPDH) were diluted 1/10000 and 1/2000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1/10000 dilution for 1 h at room temperature before imaging.
All lanes: Western blot - Anti-PKC delta (phospho S645) antibody [EP1486Y] (ab108972)
Predicted band size: 78 kDa
Primary ab Dilution 1:100,000 dilution, Secondary ab Goat Anti-Rabbit IgG, (H+L), HRP conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051), Secondary ab dilution 1:20,000 dilution,
Blocking buffer and concentration 5% NFDM/TBST, Diluting buffer and concentration 5% NFDM/TBST,
Lane 1: THP-1 whole cell lysate treated with Calyculin A with no peptides,
Lane 2: THP-1 whole cell lysate treated with Calyculin A with PKCd S645Pho peptides,
Lane 3: THP-1 whole cell lysate treated with Calyculin A with PKCd unmodified peptides,
Observed MW 78 kDa,
Exposure time 10 seconds
All lanes: Western blot - Anti-PKC delta (phospho S645) antibody [EP1486Y] (ab108972)
Predicted band size: 78 kDa
Primary ab Dilution 1:100,000 dilution, Secondary ab description and code (ab id) Goat Anti-Rabbit IgG, (H+L), HRP conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051), Secondary ab dilution 1: 20,000 dilution, Blocking buffer and concentration 5% NFDM/TBST, Diluting buffer and concentration 5% NFDM/TBST, Lane 1: Untreated THP-1 (Human monocytic leukemia cell line) whole cell lysates 15ug, Lane 2: THP-1 (Human monocytic leukemia cell line) treated with 50nM Calyculin A for 60 minutes whole cell lysates 15ug. Lane 3: THP-1 (Human monocytic leukemia cell line) treated with 50nM Calyculin A for 60 minutes' whole cell lysates 15ug. Then the membrane was incubated with phosphatase. Lane 4: None, Observed MW 78 kDa, Exposure time 5 seconds
All lanes: Western blot - Anti-PKC delta (phospho S645) antibody [EP1486Y] (ab108972)
Predicted band size: 78 kDa
Primary ab dilution 1: 1000 dilution (2.355 μg /ml), Secondary ab description and code (ab id) Goat Anti-Rabbit IgG, (H+L), HRP conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051), Secondary ab dilution 1:100,000 dilution, Blocking buffer and concentration 5% NFDM/TBST, Diluting buffer and concentration 5% NFDM /TBST, Lane 1: PKCd S645Pho peptides, Lane 2: PKCd unmodified peptides, Lane 3: None, Lane 4: None, Observed MW N/A, Exposure time 3 minutes
Antigen PKCd S645Pho peptide, PKCd S645Pho unmodified peptide, Antigen concentration 1000ng/ml, Primary antibody concentration range 0~1000ng/ml, Secondary antibody Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), Secondary antibody concentration 1:2500 dilution
Immunohistochemical analysis of PKC delta in paraffin embedded Human breast carcinoma tissue, using ab108972 at a 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin-embedded Human bladder carcinoma labeling PKC delta with ab108972 at 1/500 dilution (0.60 ?g/ml). Positive staining on human bladder carcinoma without alkaline phosphatase treatment (image A). No signal was detected when tissues were treated with alkaline phosphatase (image B). The section was incubated with ab108972 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin. Heat mediated antigen retrieval was performed with Bond™ Epitope Retrieval Solution 2 (pH 9.0) for 20 minutes.
Immunohistochemical analysis of paraffin-embedded Human spleen carcinoma labeling PKC delta with ab108972 at 1/500 dilution (0.60 ?g/ml). Positive staining on human spleen carcinoma without alkaline phosphatase treatment (image A). No signal was detected when tissues were treated with alkaline phosphatase (image B). The section was incubated with ab108972 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin. Heat mediated antigen retrieval was performed with Bond™ Epitope Retrieval Solution 2 (pH 9.0) for 20 minutes.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com